Mavacamten

Mavacamten (mavacamtene) is a prescription medication used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM). HCM is a condition where the heart muscle thickens and makes it harder for the heart to pump blood. Mavacamten helps relax the thickened heart muscle, allowing blood to flow more easily and reducing symptoms such as shortness of breath and chest pain. It is only available as an oral tablet and should be taken once daily. Mavacamten has been shown to be safe and effective in treating HCM and improving quality of life.

Mavacamten is a medication specifically designed to address a certain heart condition known as obstructive hypertrophic cardiomyopathy (HCM) [WebMD]. Here's a breakdown of its key features:

  • Purpose: Mavacamten is prescribed to adults experiencing symptoms of HCM, classified as New York Heart Association (NYHA) class II or III [WebMD, DrugBank]. NYHA is a system for classifying heart failure severity. Class II and III indicate noticeable limitations in physical activity due to heart problems.
  • Mechanism of action: Mavacamten belongs to a drug class called cardiac myosin inhibitors [DrugBank]. It works by reducing the interaction between actin and myosin, proteins essential for heart muscle contraction. By lowering this interaction, mavacamten helps the heart muscle relax more, ultimately improving blood flow [MedlinePlus].
  • Benefits: The primary benefit of mavacamten is to improve functional capacity and alleviate symptoms associated with HCM, such as shortness of breath and fatigue [WebMD]. Studies suggest it can improve NYHA class and other heart function parameters [NCBI Bookshelf].
  • Form and administration: Mavacamten comes in capsule form and is typically taken orally [WebMD].

Important points to consider:

  • Mavacamten is a relatively new medication, having received FDA approval in 2022 [DrugBank].
  • It's crucial to consult with a doctor to determine if mavacamten is the right treatment for your specific case.
  • There can be side effects associated with mavacamten, so discussing them with your doctor is essential [WebMD].
     
Anatomical Therapeutic Chemical Classification
C - Cardiovascular system
C01 Cardiac therapy
C01E - Other cardiac preparations
C01EB Other cardiac preparations
External Links